NCT05635266 Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives Status RECRUITING Phase N/A
NCT05632354 GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) Status TERMINATED Phase PHASE2/PHASE3
NCT05632289 Osteopathic Manipulation in the Management of Pain Associated With Sickel Cell Disease Status RECRUITING Phase NA
NCT05618301 Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) Status COMPLETED Phase PHASE1
NCT05605366 Minocycline In Neurocognitive Outcomes - Sickle Cell Disease Status NOT_YET_RECRUITING Phase PHASE1
NCT05583721 Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET Status RECRUITING Phase PHASE2
NCT05572294 Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease Status COMPLETED Phase NA
NCT05564845 Brain Structure and Neurocognitive Development in Sickle Cell Disease; a Longitudinal Cohort Study (BRICK Study) Status UNKNOWN Phase N/A
NCT05530239 Nano-rheological Biomarkers for Patients With Sickle Cell Disease (SCD) Versus Control Subjects (Other Constitutional Red Blood Cell Diseases and Healthy Subjects) Status NOT_YET_RECRUITING Phase N/A
NCT05519111 Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain Status RECRUITING Phase PHASE2
NCT05506358 Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada Status COMPLETED Phase NA
NCT05477563 Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Status RECRUITING Phase PHASE3
NCT05470998 L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity Status COMPLETED Phase PHASE3
NCT05470270 Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease. Status COMPLETED Phase PHASE2
NCT05469828 Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia Status NOT_YET_RECRUITING Phase PHASE1/PHASE2